What happened: An Arkansas appeals court ruled that more than 30 insurers must defend Walmart in over 2,400 opioid lawsuits under their CGL and excess liability policies.
Who's involved: Walmart and insurers across primary, excess, and quota share layers, including AIG, ACE American, QBE, Zurich, and Travelers.
What's at stake: Defense costs across thousands of opioid lawsuits filed by individuals, state attorneys general, municipalities, and healthcare entities.
Why it matters: The ruling applies the gravamen test, finding that opioid complaints against Walmart allege negligence - not intentional malfeasance - triggering the duty to defend under standard CGL occurrence language.
Where it stands: Affirmed on appeal. The broader coverage litigation in Benton County Circuit Court continues.
Thirty-plus insurers, 2,400-plus lawsuits, and one retail pharmacy caught in the middle of the opioid crisis. Who picks up the defense tab?
The Arkansas Court of Appeals answered on October 7, affirming that Walmart's CGL and excess insurers must defend it against the wave of opioid litigation that began in 2017. The court also rejected QBE Insurance Corporation's bid to compel arbitration.
Walmart filed the underlying action in Benton County Circuit Court in November 2022, seeking confirmation that insurers spanning primary, excess, and quota share layers were obligated to fund its defense. The opioid lawsuits come from three directions: individuals alleging personal harm, state attorneys general seeking to recover public costs, and healthcare entities claiming unreimbursed treatment expenses.
The insurers argued the complaints allege intentional conduct - not an "accident" - so no "occurrence" triggers coverage.
The court applied what Arkansas calls the gravamen test and disagreed. The essence of the claims against Walmart is that the retailer failed to maintain effective controls to identify and report suspicious opioid orders - language rooted in negligence, not intent. Even if Walmart intentionally filled prescriptions without proper safeguards, the court held, a nationwide addiction crisis was not necessarily a foreseeable result.
That distinction - between intending an action and intending the harm - cleared the threshold for a mere possibility of coverage, enough to trigger the duty to defend.
The excess insurers argued governmental and healthcare plaintiffs were not claiming covered "bodily injury" because they sought reimbursement for institutional costs. The court pointed to policy language covering damages claimed by "any person or organization" for care, loss of services, or death resulting from bodily injury. An organization does not have a body. The policies plainly contemplate claims beyond individual personal injury.
QBE argued its quota share policy incorporated an arbitration clause from a co-layer Endurance policy. The court read the incorporation clause narrowly: it adopted only coverage-related terms, not arbitration. Even if incorporated, Arkansas law has voided arbitration clauses in insurance contracts since 1917.
The duty-to-defend question is resolved, but the broader coverage fight continues. For coverage professionals working with layered programs, courts will look past the labels plaintiffs attach to their claims and focus on what is actually alleged.
The underlying opioid lawsuits have not been adjudicated on the merits. This ruling addresses only the insurers' obligation to defend.
